Adma Biologics, INC Form 4 insider transactions

Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of Adma Biologics, Inc., reported a transaction in 3,177 shares of common stock on July 24, 2026.

Terry Kohler, CFO and Treasurer of Adma Biologics, Inc., reported multiple transactions in common stock on July 16, 2026.

ADMA Biologics Director Jerrold B. Grossman acquired 6,400 shares of common stock in an open market transaction.

Jerrold Grossman, a Director at ADMA Biologics, Inc., reported the acquisition of 12,500 shares of common stock on May 12, 2026.

Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics common stock in an open market transaction.

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported a transaction involving 20,362 shares of common stock on April 1, 2026, primarily for tax withholding purposes.

ADMA Biologics Director Lawrence P. Guiheen exercised stock options and subsequently gifted a portion of his common stock to an irrevocable trust.

ADMA Biologics President and CEO, Adam S. Grossman, executed a pre-planned sale of common stock following the exercise of stock options.

ADMA Biologics President and CEO Adam S. Grossman reported the withholding of 54,858 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the withholding of 8,161 shares for tax obligations related to RSU vesting.

ADMA Biologics' CFO, Brad L. Tade, reported a mandatory withholding of 6,479 shares to cover tax obligations upon the vesting of restricted stock units.

ADMA Biologics President and CEO Adam S. Grossman reported a routine transaction involving the withholding of shares for tax purposes upon the vesting of restricted stock units.

ADMA Biologics Director Jerrold B. Grossman acquired 10,690 restricted stock units and 17,730 stock options, increasing his beneficial ownership in the company.

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, was granted 91,631 restricted stock units and 144,230 stock options.

ADMA Biologics' President and CEO, Adam S. Grossman, reported new grants of restricted stock units and stock options.

ADMA Biologics Director Young Kwon acquired 10,690 restricted stock units and 17,730 stock options, increasing beneficial ownership.

ADMA Biologics Director Alison Finger received grants of 10,690 restricted stock units and 17,730 stock options, increasing her beneficial ownership.

ADMA Biologics Director Eduardo Rene Salas received grants of 10,690 restricted stock units and 17,730 stock options, aligning his interests with shareholders.

ADMA Biologics Director Lawrence P. Guiheen increased his beneficial ownership through the acquisition of restricted stock units and stock options.

ADMA Biologics Director Steve Elms reported acquiring 10,690 restricted stock units and 17,730 stock options, increasing his direct and indirect beneficial ownership.

ADMA Biologics' President and CEO, Adam S. Grossman, filed a Form 4 detailing a future exercise of stock options and sale of common stock under a 10b5-1 trading plan.

ADMA Biologics President and CEO, Adam S. Grossman, exercised stock options and subsequently sold 21,000 shares of common stock for $16 per share, as part of a pre-arranged 10b5-1 trading plan.

ADMA Biologics President and CEO Adam S. Grossman executed a pre-arranged sale of 21,000 shares of common stock on October 24, 2025, following the exercise of options.

ADMA Biologics President and CEO Adam S. Grossman exercised stock options and subsequently sold a portion of his common stock holdings totaling 21,000 shares, pursuant to a Rule 10b5-1 plan.

ADMA Biologics CEO Adam S. Grossman executed a pre-planned sale of company stock, acquiring shares via option exercise and immediately selling them.

ADMA Biologics' Chief Operating Officer and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the exercise of employee stock options and subsequent share disposition for tax purposes.

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the withholding of 3,027 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

ADMA Biologics' CFO and Treasurer, Brad L. Tade, reported a disposition of 7,123 shares of common stock, representing a routine tax withholding upon the vesting of restricted stock units.

ADMA Biologics President and CEO Adam Grossman exercised stock options and sold a portion of his common stock holdings on July 15, 2025, as part of a pre-established Rule 10b5-1 trading plan.

ADMA Biologics' CFO and Treasurer, Brad L. Tade, reported a change in beneficial ownership, with 9,838 shares withheld for tax purposes upon the vesting of restricted stock units, leaving a total beneficial ownership of 246,542 shares.